Clarithromycin as a "repurposing drug" against MALT lymphoma

Br J Haematol. 2018 Sep;182(6):913-915. doi: 10.1111/bjh.14878. Epub 2017 Aug 2.

Authors

Andrés J M Ferreri¹, Caterina Cecchetti¹, Barbara Kiesewetter², Marianna Sassone¹, Teresa Calimeri¹, Salvatore Perrone¹, Maurilio Ponzoni³, Markus Raderer²

Affiliations

¹ Unit of Lymphoid Malignancies, Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milano, Italy.
² Clinical Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
³ Ateneo Vita-Salute San Raffaele University, Pathology Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy.

PMID: 28771670
DOI: 10.1111/bjh.14878

No abstract available

Keywords: MALT lymphoma; clarithromycin; indolent lymphomas; repurposing drugs.

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Clarithromycin / administration & dosage
Clarithromycin / therapeutic use*
Dose-Response Relationship, Drug
Drug Repositioning / economics
Drug Repositioning / methods*
Drug Repositioning / standards
Female
Follow-Up Studies
Humans
Lymphoma, B-Cell, Marginal Zone / drug therapy*
Male
Middle Aged
Remission Induction
Retrospective Studies
Treatment Outcome

Substances

Clarithromycin